Edwards Lifesciences Corp (EW)vsInMode Ltd (INMD)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
INMD
InMode Ltd
$14.90
+0.88%
HEALTHCARE · Cap: $860.28M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1638% more annual revenue ($6.51B vs $374.63M). INMD leads profitability with a 20.7% profit margin vs 15.4%. EW appears more attractively valued with a PEG of 1.92. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
INMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Margin of Safety
+59.5%
Fair Value
$35.20
Current Price
$14.90
$20.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
0.0% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : INMD
The strongest argument for INMD centers on Price/Book, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 20.7% and operating margin at 12.8%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : INMD
The primary concerns for INMD are Revenue Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
EW profiles as a mature stock while INMD is a value play — different risk/reward profiles.
INMD carries more volatility with a beta of 1.87 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 52/100), backed by strong 15.4% margins and 13.6% revenue growth. INMD offers better value entry with a 59.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →InMode Ltd
HEALTHCARE · MEDICAL DEVICES · USA
InMode Ltd. designs, develops, manufactures and markets minimally invasive aesthetic medical products based on its proprietary RF-assisted lipolysis and deep subdermal fractional RF technologies. The company is headquartered in Yokneam, Israel.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?